Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Time to blur the blast boundaries

8 Feb 2022

Abstract excerpt

A fixed 20% blast percentage to discriminate myelodysplastic neoplasms from acute myeloid leukemia is arbitrary and overly simplistic. Key factors for identifying the optimal therapy for a patient with a myeloid malignancy should rely most on the patient's characteristics (particularly age and fitness/frailty) and disease cytogenetic and mutational profile, with less reliance on the bone marrow blast percentage.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Hematological disorders and diagnostics
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35133004
DOI: 10.1002/cncr.34119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Time to blur the blast boundariesPMID 35133004Read ↗

Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.Semantic proximity Read ↗

Incorporation mutational profile might reduce the importance of blast count in prognostication of low-risk myelodysplastic syndromes.Semantic proximity Read ↗

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.Semantic proximity Read ↗

The Biology of CML blast crisis.Semantic proximity Read ↗

Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging DiseaseSemantic proximity Read ↗

Lowering the boom on lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?Semantic proximity Read ↗

How I treat CML blast crisisSemantic proximity Read ↗

The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the Minnesota experience.Semantic proximity Read ↗

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.Semantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.